Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

  • Author: Paul E. Sax, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/5/18 (What's New)

Summary

  • 3 boosted PIs are currently included among choices for first-line therapy in US and European guidelines
  • Atazanavir is included as an alternative option in the DHHS and EACS guidelines[DHHS ART; EACS ART]
  • Darunavir is included as an alternative option in the DHHS, IAS-USA, and EACS guidelines[DHHS ART; IAS-USA ART; EACS ART]
    • Boosted Atazanavir-Based Initial Therapy
      Atazanavir + Ritonavir Initial Therapy
        Atazanavir/Cobicistat-Based Initial Therapy
        Boosted Darunavir-Based Initial Therapy
          Darunavir/Ritonavir Initial Therapy
            Darunavir/Cobicistat-Based Initial Therapy
            Lopinavir/Ritonavir-Based Initial Therapy

            Action required

            Keywords: Initial Antiretroviral Therapy

            ©2018 Clinical Care Options, LLC. All Rights Reserved.

            The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.